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ABSTRACT Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease and a leading
cause of mortality and morbidity worldwide. The aim of this study was to investigate the sex dependency
of circulating metabolic profiles in COPD.
Serum from healthy never-smokers (healthy), smokers with normal lung function (smokers), and
smokers with COPD (COPD; Global Initiative for Chronic Obstructive Lung Disease stages I–II/A–B) from
the Karolinska COSMIC cohort (n=116) was analysed using our nontargeted liquid chromatography–high
resolution mass spectrometry metabolomics platform.
Pathway analyses revealed that several altered metabolites are involved in oxidative stress. Supervised
multivariate modelling showed significant classification of smokers from COPD (p=2.8×10−7). Sex
stratification indicated that the separation was driven by females (p=2.4×10−7) relative to males (p=4.0×10−4).
Significantly altered metabolites were confirmed quantitatively using targeted metabolomics. Multivariate
modelling of targeted metabolomics data confirmed enhanced metabolic dysregulation in females with COPD
(p=3.0×10−3) relative to males (p=0.10). The autotaxin products lysoPA (16:0) and lysoPA (18:2) correlated
with lung function (forced expiratory volume in 1 s) in males with COPD (r=0.86; p<0.0001), but not females
(r=0.44; p=0.15), potentially related to observed dysregulation of the miR-29 family in the lung.
These findings highlight the role of oxidative stress in COPD, and suggest that sex-enhanced
dysregulation in oxidative stress, and potentially the autotaxin–lysoPA axis, are associated with disease
mechanisms and/or prevalence.
This article has supplementary material available from erj.ersjournals.com
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Introduction
Chronic obstructive pulmonary disease (COPD) is an umbrella diagnosis that is characterised by airflow
obstruction and permanent reduction of the forced expiratory volume [1]. COPD-related mortality is estimated
to reach 1 billion by the end of the 21st century [2]. The early diagnosis of COPD is challenging due to disease
heterogeneity and lack of predictive molecular markers. The diagnosis is based solely on spirometry, while lung
function, symptoms and exacerbation history are used for disease staging. Decline in lung function over time is
accepted as a reliable index of disease progression; however, the mechanisms underlying different COPD
subphenotypes and their relationship with prognosis are still unclear [3]. For example, evidence of sex
differences, with higher mortality in females even after correction for smoking has emerged [4]. Smoking
results in greater impairment in lung function in females, especially post-menopause [5, 6].
Cigarette smoking exerts extensive airway epithelial damage and is an important component driving the
onset of COPD [7]. However, not all smokers develop COPD and disease severity varies among smoking
COPD individuals. Other risk factors include genetics, asthma, environmental exposures, premature birth
and persistent respiratory infections in early childhood [8, 9]. In addition, COPD pathogenesis may be
linked to oxidative stress resulting from the overproduction of oxidants/reactive oxygen species (ROS),
arising endogenously (e.g. from mitochondrial respiration or immune cells) or exogenously (e.g. tobacco
smoke) [10, 11].
The aim of the current study was to employ a nontargeted high-resolution mass spectrometry (HRMS)
metabolomics approach to identify molecular markers of metabolic dysregulation in COPD using the
Karolinska COSMIC (Clinical & Systems Medicine Investigations of Smoking-related Chronic Obstructive
Pulmonary Disease) cohort [12–15]. A particular focus of the COSMIC study is to evaluate the role of sex
in the aetiology of COPD. Accordingly, our statistical analysis focused on sex-specific shifts in the
observed metabolic pathways.
Materials and methods
Subjects and study design
The Karolinska COSMIC cohort (www.clinicaltrials.gov/ct2/show/NCT02627872) is a three-group
cross-sectional study designed for investigating molecular sex differences in early-stage COPD, including 40
never-smokers (“healthy”), 40 smokers with normal lung function (“smokers”) and 38 individuals with COPD
(Global Initiative for Chronic Obstructive Lung Disease stage I–II/A–B; forced expiratory volume in 1 s (FEV1)
51–97%; FEV1/forced vital capacity (FVC) <70%; 27 current smokers (“COPD”) and 11 ex-smokers
(“COPD-ExS”)) [12–15]. Of the 118 recruited individuals, two never-smokers did not provide a blood sample
and were excluded from the analysis. The remaining 116 subjects were matched for age, sex and current
smoking status, and history where relevant (table 1 and online supplementary table E1). Blood was drawn
from fasting individuals by venipuncture between 07:00 h and 09:00 h and allowed to stand at room
temperature for ⩾30 min before centrifugation at 1695×g for 10 min at room temperature, and stored at −80°C
until use. During the same visit, bronchoalveolar lavage (BAL) was performed and bronchial epithelial cell
(BEC) brushings were collected. Detailed methods, as well as study inclusion and exclusion criteria are
provided in the online supplementary material. The study was approved by the Stockholm regional ethical
board (case number 2006/959-31/1) and participants provided their informed written consent.
Mass spectrometry analysis
Sample processing and analyses were performed as previously published [16] and are described in the
online supplementary material. Briefly, for nontargeted metabolomics, 50 μL of serum was used for both
hydrophilic interaction liquid chromatography (HILIC) and reversed-phase (RP) chromatography. Samples
were analysed using an Ultimate 3000 UHPLC coupled to a Q-Exactive Orbitrap mass spectrometer
(Thermo Fisher Scientific, Bremen, Germany). Mass spectrometry (MS) data were acquired (full scan
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TABLE 1 Clinical parameters of individuals from the Karolinska COSMIC cohort included in the current study
Healthy never-smokers Smokers COPD COPD ex-smokers
Male Female Male Female Male Female Male Female
Subjects 20 18 20 20 15 12 5 6
Age years 62.0 (51.5–64.0) 55.5 (47.8–62.0) 52.5 (49.0–56.0) 54.0 (48.0–58.0) 61.0 (55.0–63.0) 59.0 (57.0–63.0) 64.0 (58.0–65.5) 58.0 (53.8–65.0)
BMI kg·m-2 25.6 (23.5–27.9) 26.5 (23.3–30.6) 25.0 (21.9–26.2) 24.2 (22.6–25.9) 24.2 (21.3–28.7) 23.5 (20.8–26.0) 29.1 (24.0–31.0) 27.6 (22.3–29.6)
Smoking pack-years NA NA 33.5 (30.0–40.0) 33.0 (27.3–40.0) 42.0 (36.0–50.0) 40.5 (35.8–47.3) 30.0 (21.5–39.5) 28.5 (19.3–37.8)
Menopause no/yes NA 12/6 NA 8/12 NA 0/12 NA 1/5
GOLD stage 1/2 NA NA NA NA 7/7 6/6 2/3 4/2
GOLD-2011 A/B/C NA NA NA NA 11/4/0 9/3/0 3/1/1 4/2/0
Blood leukocytes ×109·L-1 5.8 (4.8–6.7) 5.6 (5.0–6.8) 7.4 (6.9–8.3) 6.8 (6.3–8.0) 7.8 (6.4–9.2) 8.2 (5.9–10.2) 6.6 (5.5–7.5) 7.0 (6.5–9.3)
Blood platelets ×109·L-1 216.0 (193.3–246.8) 267.5 (244.5–307.8) 239.0 (209.0–272.0) 287.5 (241.5–346.3) 264.0 (224.0–345.0) 280.5 (235.8–329.5) 199.0 (196.0–285.0) 244.5 (207.0–327.8)
Serum albumin g·L−1 40.0 (38.0–42.0) 40.0 (37.8–41.0) 39.0 (38.0–41.0) 39.0 (37.3–39.8) 38.0 (37.0–38.0) 39.5 (38.0–41.0) 38.0 (36.5–39.5) 41.0 (39.3–42.0)
Antitrypsin g·L−1 1.4 (1.3–1.5) 1.4 (1.3–1.5) 1.4 (1.3–1.6) 1.6 (1.4–1.7) 1.6 (1.4–1.7) 1.6 (1.4–1.7) 1.4 (1.3–1.7) 1.4 (1.2–1.6)
FEV1 % 119.0 (104.0–127.5) 120.5 (111.0–127.3) 107.0 (103.3–118.5) 110.0 (98.3–116.0) 78.0 (73.0–84.0) 78.5 (74.3–93.5) 72.0 (58.0–91.0) 83.5 (73.8–90.8)
FEV1/FVC % 80.0 (76.3–84.8) 82.5 (76.8–84.3) 77.0 (74.3–80.0) 79.0 (74.3–82.5) 64.0 (56.0–66.0) 61.5 (53.8–63.5) 59.0 (48.5–68.0) 64.0 (56.5–66.3)
Emphysema no/yes NA NA 10/10 7/13 5/10 1/11 1/4 4/2
Chronic bronchitis no/yes NA NA 13/7 13/7 13/2 7/5 1/4 5/1
Data are presented as n or median (interquartile range). COPD: chronic obstructive pulmonary disease; BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung
Disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; NA: not applicable.
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mode) in both positive and negative ionisation. Molecular features were extracted using the software
XCMS (https://metlin.scripps.edu). Putative metabolite annotation was performed using the Human
Metabolome Database (HMDB) [17], and output matched to an in-house accurate mass/retention time
library of reference standards [18]. Metabolite identity was described as confirmed following a match to
reference standards and/or MS/MS. Targeted metabolite quantification was performed using the Biocrates
AbsoluteIDQ p180 kit (Biocrates Life Sciences, Innsbruck, Austria) on a Xevo TQ-S triple quadrupole
(Waters Corporation, Milford, MA, USA).
miRNA profiling
miRNA from BAL cells and BECs, and exosomes from BAL fluid from a subset of the COSMIC cohort
based upon sample availability (n=45; five to 13 subjects per group and sex) were analysed as described in
the online supplementary material. Statistical analyses were performed on probe intensities from a subset
of four miRNAs of interest, selected using TargetScan release 7.1 ( June 2016): miR-29a-3p, miR-29b-3p,
miR-29c-3p targeting autotaxin (ENPP2) and miR-218-5p targeting N-acyl phosphatidylethanolamine
phospholipase D (NAPE-PLD).
Statistical analysis
Due to the confounding effects of smoking, stratification by smoking status was applied in both univariate
and multivariate statistical analyses. Accordingly, the smoking population (smokers and COPD) and
nonsmoking population (healthy and COPD-ExS) were analysed separately. Statistical analysis was applied
to metabolites present in ⩾70% of the samples in at least one group, with a coefficient of variation <30%
in quality control samples [19]. The percentage of missing values was compared across all clinical groups
prior to removal, to ensure that a metabolite was not erroneously removed due to being absent completely
in one or more groups. Metabolites with a quality control relative standard deviation >25% were deemed
not suitably reproducible and removed from further analysis; this value was chosen based on literature
reports [20] and our choice of chromatography (RP and HILIC). Four samples were not analysed in
HILIC positive mode due to lack of material, for which missing values were imputed using k-nearest
neighbours (k=10) imputation [21].
Univariate statistical analysis was performed on filtered data using the Mann–Whitney test and the Storey
q-value (MATLAB vR2015a; MathWorks, Natick, MA, USA). Correction for p-values with regards to age
and smoking history between smokers and COPD groups was performed in STATA (v12; StataCorp,
College Station, TX, USA) (online supplementary table E2).
Multivariate statistical modelling was performed on log-transformed, mean-centered and pareto-scaled data
using SIMCA (v14.0; MKS Umetrics, Malmö, Sweden). Orthogonal projections to latent structures
discriminant analysis (OPLS-DA) was performed using metabolites that passed quality control. OPLS-DA
models were optimised using variable selection criteria of |p(corr)|⩾0.4 (loadings scaled as correlation
coefficient between model and original data) and variable importance in projection ⩾1.0 as previously
described [22]. Model statistics are reported by the cumulative correlation coefficient (R2Y), the predictive
variance based on seven-fold cross-validation (Q2) and cross-validated ANOVA p-values for OPLS models.
Shared-and-unique-structure (SUS) analysis correlating p(corr) values between models was performed as
previously described [23]. A short tutorial on the multivariate methods is provided in the online
supplementary material. Pathway enrichment analysis on structurally confirmed metabolites was performed
using integrated pathway-level analysis [24]. In addition, we performed stratification by sex prior to univariate
and multivariate statistical analyses to facilitate investigation of inter- and intra-group sex differences.
Additionally, investigations of the effects of menopause were performed by construction of multivariate models
including and excluding premenopausal females, and correlating these models through SUS-based analysis.
Results
Smokers versus COPD using nontargeted metabolomics
Univariate statistical data analysis
A metabolite is described as “putative” following an accurate mass match to the HMDB database [17]. A
metabolite is described as “confirmed” following a match to reference standards and/or MS/MS spectrum. A
total of 1153 putative metabolites were extracted from the nontargeted metabolomics raw data, of which 959
passed quality control. These putative metabolites were subjected to both sex-combined and sex-stratified
comparisons of smokers versus COPD. Of the 959 putative metabolites, 184 were significant at p<0.05 and
selected for structural confirmation. Of these 184 metabolites, 67 were structurally confirmed by MS/MS
and/or matching to reference standards, and the corresponding p-value, Storey’s q-value and fold change are
provided in online supplementary table E2. All nontargeted metabolomics data presented in this study refer
to these 67 structurally confirmed metabolites.
https://doi.org/10.1183/13993003.02322-2016 4
COPD | S. NAZ ET AL.
Multivariate statistical modelling
Multivariate statistical modelling of smokers versus COPD was performed using OPLS-DA on the 67
confirmed metabolites. The joint sex OPLS-DA model for classifying smokers versus COPD showed
significant group separation (R2Y=0.45, Q2=0.38, p=2.8×0−7; online supplementary figure E1), with a
receiver operating characteristic area under the curve (AUC) of 0.90. Sex stratification revealed that the
group separation in smokers versus COPD was more robust in females (R2Y=0.73, Q2=0.65, p=2.4×0−7,
AUC=1.0) relative to males (R2Y=0.49, Q2=0.38, p=4.0×0−4, AUC=0.89) (figure 1). Permutation tests
confirmed the robustness of the models (Y-intercept (500 permutations): females R2Y=0.24, Q2=−0.18;
males R2Y=0.20, Q2=−0.26; figure not shown). Only 13 metabolites overlapped all three models (online
supplementary figure E2).
Correlations were performed for all significantly altered metabolites with lung function parameters (FEV1 (%)
and FEV1/FVC) using Spearman’s correlation, as well as group-wise using partial least squares multivariate
correlation (online supplementary figure E3). Lysophosphatidic acid (lysoPA) (16:0) and lysoPA (18:2) were
most strongly correlated with FEV1 (%), and were further stratified by sex, evidencing strong correlations in
male COPD patients (partial least squares inner relation: r=0.86, p<0.0001) (figure 2), but not females (r=0.44,
p=0.15). Based upon these findings, the serum levels of lysoPA (16:0) and lysoPA (18:2) were examined and
found to exhibit greater increases in females with COPD relative to smokers (p=0.0003 and p=0.0005,
respectively) than the corresponding males (p=0.04 and p=0.03, respectively) (figure 2).
All females in the COPD group were postmenopausal, while 40% (n=8) female smokers were premenopausal.
To investigate the role of menopausal status, OPLS-DA models including only postmenopausal subjects were
constructed, and correlated with the original model based on all female subjects using SUS analyses. The high
correlation between the two models (R2=0.92) indicates that no substantial differences in metabolite levels
were observed due to menopausal status (online supplementary figure E4).
Pathway enrichment analysis
Pathway analysis of the COPD-associated metabolic perturbations from the nontargeted metabolomics
data identified significant shifts (p⩽0.05) in eight biochemical pathways (table 2), with COPD-associated
increase in metabolites of the tricarboxylic acid (TCA) cycle, glycerophospholipids, cAMP signalling,
endocannabinoids, sphingolipid and fatty acid metabolism. Sex-stratified pathway analyses established that
the fatty acid and sphingolipid pathways were enhanced in females, whereas shifts in cAMP signalling and
endocannabinoid and tryptophan metabolism pathways were enhanced in males. The altered metabolic
changes based upon the pathway analysis also highlight a strong state of oxidative stress in COPD.
Confirmation of oxidative stress results by targeted MS
Metabolites related to oxidative stress were identified as one of the primary drivers for differentiating the
smokers and COPD groups (online supplementary table E2). A targeted MS platform (Biocrates
AbsoluteIDQ p180 kit) was applied to confirm this finding. Among the 188 metabolites analysed, nine
were excluded from further statistical analysis due to ⩾70% missing values and/or values below the limit of
detection. Measured concentrations of each metabolite as well as the corresponding p-value and q-value
are shown in online supplementary table E3. The greatest differences were observed for the female
comparisons (smokers versus COPD, 26 metabolites p<0.05) relative to the males (smokers versus COPD,
11 metabolites p<0.05), confirming the results of the nontargeted metabolomics platform.
OPLS-DA analysis based on the targeted data confirmed significant separation between the smokers and
COPD groups (R2Y=0.29, Q2=0.19, p=2.0×10−3). Sex stratification confirmed that the separation between
smokers and COPD was driven by the female population (R2Y=0.45, Q2=0.34, p=3.0×10−3), with no
significant model for males (p=0.10) (online supplementary figure E5).
The relative level of fatty acid β-oxidation was estimated by the ratio of carnitine to acylcarnitine using the
sum of short-, medium- and long-chain carnitines. The ratios between medium- and long-chain carnitines
were significantly downregulated in the female COPD group versus smokers (p=0.01 and p=0.02,
respectively), but not in the corresponding male population (figure 3a and b).
Perturbations in nitric oxide synthesis were examined via metabolites of the arginine pathway. The ratios
of acetyl–ornithine/ornithine and arginine/(citrulline+ornithine) were significantly lower in females with
COPD versus smokers (p=0.006 and p=0.01, respectively; figure 4a and b), but not the corresponding male
subjects. Conversely, the ratio of asymmetric (ADMA) and symmetric dimethylarginine (SDMA) to
arginine as well as ADMA alone was significantly upregulated in females with COPD (p=0.04 and p=0.04,
respectively; figure 4c and d), with no differences in male subjects.
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FIGURE 1 Optimised orthogonal projections to latent structures discriminant analysis multivariate models using nontargeted metabolomics data.
a) i) Scores plot of male smokers versus males with chronic obstructive pulmonary disease (COPD) (R2Y=0.49, Q2=0.38, p=4.0×10−4); ii) loadings of
confirmed metabolites that were the most prominent for driving the separation between male smokers versus males with COPD. b) i) Scores plot
of female smokers versus females with COPD (R2Y=0.73, Q2=0.65, p=2.4×10−7); ii) loadings of confirmed metabolites that were the most prominent
for driving the separation of female smokers versus females with COPD. For ease of display, parts a ii) and b ii) exclude metabolites whose
standard error crossed the x-axis. The complete list of loadings is shown in online supplementary figure E8. LysoPA: lyso-phosphatidic acid;
HETE: hydroxyeicosatetraenoic acid; HDoHE: hydroxydocosahexaenoic acid; EpETrE: epoxyeicosatrienoic acid; HEDE: hydroxyeicosadienoic acid;
AEA: N-arachidonoylethanolamine; OEA: N-oleoylethanolamine; EpODE: epoxyoctadecadienoic acid; PEA: N-palmitoylethanolamide; Asp-Leu:
aspartic acid-leucine.
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FIGURE 2 The lyso-phosphatidic acid (lysoPA)–autotaxin axis was attenuated in males with chronic obstructive
pulmonary disease (COPD). a) Serum lysoPA (16:0) levels in smokers versus COPD; (b) serum lysoPA (18:2)
levels in smokers versus COPD; (c) lysoPA (16:0) and lysoPA (18:2) metabolites correlated with lung function
(forced expiratory volume in 1 s (FEV1)) in male COPD patients (r=0.84, p<0.0001). No correlation was
observed in the corresponding female COPD population (r=0.44, p=0.15); (d) levels of miR-29b in
bronchoalveolar lavage (BAL) cells from male and female smokers and COPD patients. Values for the other
members of the miR-29 family are shown in online supplementary figure E6. LysoPA data are from the
nontargeted metabolomics platform and are presented as log2 of arbitrary units (AU). RFU: relative
fluorescence units; LLOQ: lower limit of quantification.
TABLE 2 Metabolic pathways significantly altered in chronic obstructive pulmonary disease (COPD)#
Pathway name(s) Number of
metabolites in pathway
Smokers versus COPD
Both sexes Female Male
Hits p-value (FDR¶) Hits p-value (FDR¶) Hits p-value (FDR¶)
Alterations in both sexes
Citrate (tricarboxylic acid) cycle 3 0.0009 (0.005) 3 0.0006 (0.005) 2 0.005 (0.01)
Glycerophospholipid metabolism 52 3 0.002 (0.009) 3 0.002 (0.007) 4 <0.0001 (0.0001)
Pyruvate metabolism 31 2 0.03 (0.05) 2 0.03 (0.04) 2 0.01 (0.02)
Sex-enhanced: female COPD
Fatty acid biosynthesis 50 3 0.0002 (0.002) 2 0.006 (0.01) 0 1.0 (1.0)+
Sphingolipid metabolism 25 2 0.02 (0.05) 2 0.02 (0.03) 0 1.0 (1.0)+
Sex-enhanced: male COPD
cAMP signalling pathway 40 2 0.03 (0.05) 2 0.02 (0.03) 2 0.009 (0.02)
Retrograde endocannabinoid signalling 19 2 0.02 (0.04) 2 0.01 (0.02) 2 0.005 (0.02)
Tryptophan metabolism 80 2 0.5 (1.0)+ 0 1.0 (1.0)+ 2 0.04 (0.05)
FDR: false discovery rate. #: pathway analysis was performed using integrated pathway-level analysis [24]; ¶: calculated using Benjamini–
Hochberg method with a cut-off value of p<0.3; +: pathways did not pass the FDR cut-off value.
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Correlation to miRNA expression in the lung
Aberrant expression of miRNAs has been associated with several pulmonary disorders, including COPD
[25–27]. We therefore performed microarray profiling of the miR-29-3p family (-29a, -29b and -29c),
which are putative regulators of autotaxin (lysophospholipase D, ENPP2). We found that these miRNAs
were present at levels substantially above the limit of detection in BAL cells and BECs in both the smokers
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and COPD groups (average expression level 28–211), but not in exosomes isolated from BAL fluid. The
miR-29 family was significantly upregulated in male COPD patients compared to smokers both in BAL
cells (p=0.004–0.056, fold change 1.5–2.7; figure 2d and online supplementary figure E6) and BECs
(p=0.03–0.06, fold-change 2.0–2.8, online supplementary figure E6), while no alteration was detected in
the corresponding female cohort (BAL p=0.78–0.90; BEC p=0.22–0.29). Levels of miR-218-5p, a putative
regulator of NAPE-PLD (an alternative route of lysoPA production) previously reported to be involved in
the pathogenesis of COPD [27], were below the lower limit of quantification in all three lung
compartments (BAL cells, BECs and BAL fluid exosomes).
Healthy versus COPD-ExS
An OPLS-DA model comparing the nonsmoking population (healthy versus COPD-ExS) was correlated to
the OPLS-DA model of smokers versus COPD groups described earlier, to investigate whether the
metabolite shifts related to COPD were independent from current smoking status. SUS correlation analysis
between the models describing the nonsmoking and smoking populations was highly correlated (R2=0.73),
suggesting that the alterations observed due to COPD in the smoking population are independent of
current smoking status (online supplementary figure E7).
Discussion
The objective of the current study was to investigate systemic shifts in metabolism in early-stage COPD.
Using our suite of HRMS-based nontargeted and targeted metabolomics platforms, we observed systemic
molecular shifts in serum from smokers and early-stage COPD patients. Further stratification revealed
sex-associated metabotypes, with a subset of metabolites significantly separating female smokers and female
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COPD patients (p=2×10−7). This corresponds well with our previous findings of a female-associated
molecular subphenotype of COPD in this cohort [12, 15].
The majority of the observed COPD-related metabolic shifts were associated with oxidative stress (figure 5).
The lungs are constantly exposed to ROS, and dysregulation of oxidative stress related pathways has been
implicated in airway disease [28, 29]. The observed elevation in circulating levels of acylcarnitines in COPD
suggests an amplified energy demand that is reflected in the increased transfer of acetyl coenzyme A to the
TCA cycle (figure 5a). In this capacity, free carnitine acts as a fatty acid carrier between the mitochondria and
cytosol, and reduced levels of free carnitine in lung tissue have been reported to associate with progressive
emphysema [30]. Upregulation of the TCA cycle leads to increased ATP production (figure 5a), and increased
extracellular ATP levels in the airway lumen have been associated with COPD pathogenesis via the
recruitment and activation of inflammatory cells, accelerating inflammation and tissue degradation [31].
Following sex stratification, we observed that the majority of the oxidative stress related shifts were more
pronounced in females with COPD. These findings were confirmed by targeted analysis, identifying
sex-associated metabotypes of COPD. It has been postulated that antioxidant genes are downregulated in
smoking-induced COPD in females. In an elegant mouse study, TAM et al. [32] showed that long-term
exposure to smoking was associated with increased small airway remodelling and distal airway resistance, as
well as downregulation of a range of antioxidant genes and increased oxidative stress in female, but not male
or ovariectomised mice. These effects were attenuated by tamoxifen treatment, indicating that female sex
hormones play an important role in the sensitivity to smoking, with impairment of antioxidant defence being
a contributing factor. In our study, enhanced β-oxidation, purine degradation and endocannabinoid
production, as well as the ratios of free carnitine to medium- and long-chain acylcarnitines were significantly
increased in females relative to males (figure 3a and b). These findings provide a strong molecular signature
that substantiates the findings of TAM et al. [32], further supporting the theory of systemic dysregulation of the
antioxidant defence in a female-dominated COPD subphenotype [12, 15]. Reactive nitrogen species (RNS)
also contribute to oxidative damage in COPD. The arginine pathway is one of the major sources of RNS and
is involved in maintaining airway tone [33]. ADMA and SDMA are endogenous nitric oxide synthase (NOS)
inhibitors that are associated with COPD prognosis and airway remodelling [34, 35] as well as airway
obstruction in asthma [36]. The observed sex-selective alterations in the arginine pathway metabolites
(figure 4) suggest that in female COPD, oxidative damage is both ROS- and RNS-mediated. These findings
further support the hypothesis that nitrosative stress may be involved in the progression of COPD, with
endothelial NOS expression previously reported to increase in the bronchial submucosa of smokers [37].
While a number of metabolites shifted between smokers and COPD, both lysoPA species correlated strongest
with lung function (online supplementary figure E3). The enzyme autotaxin (lysophospholipase D) is the
primary source of lysoPA lipid mediators in blood [38], and has been suggested as a promising target for
COPD treatment [39]. The serum lysoPA levels only correlated with lung function in male COPD patients
(figure 2c), suggesting a sex-associated dysregulation in the autotaxin–lysoPA pathway. These findings were
supported by greater increases in the levels of autotaxin-regulating miRNA in BAL cells and BECs of male
COPD patients relative to females (figure 2d). Interestingly, levels of miR-29b-3p, the family member with
the highest alterations, correlated with FEV1 in male COPD patients (r=0.62, p=0.07; data not shown), but
not female COPD patients (r=0.48, p=0.16), male smokers (r=0.33, p=0.33) or female smokers (r=0.25,
p=0.75). The miR-29 family was selected for investigation based upon a TargetScan query for autotaxin;
however, there are no reports of miR-29 interacting with autotaxin in the literature, suggesting that this is a
new area of investigation. While we observed a strong upregulation in BAL cells and BECs in male COPD
patients for the entire miR-29 family, a decrease in miR-29-b has been previously reported in BAL cells from
COPD patients [25]. However, the previous study did not register or control for glucocorticoid treatment
and the authors reported that it is likely that the COPD patients in their cohort were taking inhaled
corticoids (ICS). In the Karolinska COSMIC cohort ICS use was not permitted, with a minimum 3-month
washout period. SOLBERG et al. [40] reported 1.7–2.8-fold decreases of all three miR-29s in ICS-using
asthmatics compared to healthy controls. Accordingly, the observed discrepancies in miR-29 levels are
probably due to differences in ICS treatment. While the role of miR-29 in COPD is unclear, it has been
shown to have important functions in pulmonary fibrosis [41] and lung cancer [42, 43], suggesting that it
plays a role in lung injury and highlighting the interest in targeting this pathway.
Upregulation of the autotaxin–lysoPA axis has been associated with a number of inflammatory lung
conditions, including hyperoxic lung injury [44], fibrosis [45] and asthma [46, 47]. Sex differences in the
autotaxin–lysoPA axis have been reported, with both autotaxin [48] and lysoPA [49] plasma levels higher
in females relative to males. Platelet activation can also lead to increased serum lysoPA levels via autotaxin
activity [38], and platelet involvement is supported by the observed increased in serum levels of the
12-lipoxygenase product 12-hydroxyeicosatetraenoic acid (12-HETE; q=0.01 in females, q=0.3 in males).
12-HETE plays a critical role in platelet aggregation and thrombosis [50, 51]. Based on these observations,
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it is possible that the upregulation of miR-29 exhibits a protective role against oxidative stress-mediated
shifts in the autotaxin–lysoPA axis in male, but not female COPD patients, potentially in combination
with increased platelet activation in females. However, the potential interaction between miR-29 levels in
the lung and circulatory lysoPA levels is unclear. Exosomal regulation is one potential mechanism;
however, miR-29 exosome levels were below the limit of quantification. In order to investigate the
potential mechanism, further work should determine autotaxin levels in the circulation and the airways as
well as quantify the full panel of lysoPA species in both compartments. It would be of particular interest
to examine the autotaxin mRNA levels as well as protein levels in BAL cells in order to better understand
the relationship between message, protein and metabolite profiles. The current findings suggest that the
autotaxin–lysoPA should be further investigated in the pathobiology of COPD, but studies should be
designed for sex-stratification.
This study highlights a number of interesting metabolic shifts with COPD and sex; however, there are
limitations that should be considered when interpreting the results. While the Karolinska COSMIC cohort
is a large study with regards to the invasive sampling through bronchoscopy, from a statistical standpoint
the group sizes are relatively small. Accordingly, even though the cross-validated multivariate models gave
robust classification models, an independent validation cohort is required to confirm our findings.
Furthermore, given our choice to only include confirmed metabolites in the analysis, it is likely that other
metabolic shifts occur in the pathobiology of COPD that are not observed with the current metabolite
panel. In addition, the longitudinal stability of these metabolite signatures needs to be confirmed.
Importantly, the relationship between miRNA levels in the lung compartment and lysoPA levels in
circulation is unclear, and as lysoPA can also be released from platelets during the clotting process, this
mechanistic information should be interpreted with caution.
To summarise, this study highlights the role of oxidative stress in the pathobiology of COPD. Of particular
interest is that even in early-stage COPD, strong systemic alterations were observed in oxidative stress
associated metabolic pathways. These findings further highlight the sex differences in COPD, emphasising
the importance of sex-stratification in future studies. While oxidative stress appears to be more strongly
upregulated in females with COPD, as previously reported [32] the effects may be due to an increase
in the antioxidant pathways in the corresponding male population. For example, the selective increase in
miR-29b in two lung compartments in males could potentially account for the observed sex differences
in the autotaxin–lysoPA axis and its associated pathology. In addition, it has recently been reported that
autotaxin binds to steroids [52], further opening the potential for interactions between sex hormones and
the autotaxin–lysoPA axis. Finally, as with the previous studies from the Karolinska COSMIC cohort, the
majority of the observed alterations were more pronounced in the female population, providing further
molecular evidence of a female-driven subphenotype of COPD.
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